PAI-1 secreted from metastatic ovarian cancer cells triggers the tumor-promoting role of the mesothelium in a feedback loop to accelerate peritoneal dissemination. (1st February 2019)
- Record Type:
- Journal Article
- Title:
- PAI-1 secreted from metastatic ovarian cancer cells triggers the tumor-promoting role of the mesothelium in a feedback loop to accelerate peritoneal dissemination. (1st February 2019)
- Main Title:
- PAI-1 secreted from metastatic ovarian cancer cells triggers the tumor-promoting role of the mesothelium in a feedback loop to accelerate peritoneal dissemination
- Authors:
- Peng, Yang
Kajiyama, Hiroaki
Yuan, Hong
Nakamura, Kae
Yoshihara, Masato
Yokoi, Akira
Fujikake, Kayo
Yasui, Hiroaki
Yoshikawa, Nobuhisa
Suzuki, Shiro
Senga, Takeshi
Shibata, Kiyosumi
Kikkawa, Fumitaka - Abstract:
- Abstract: The mesothelium, covered by a continuous monolayer of mesothelial cells, is the first protective barrier against metastatic ovarian cancer. However, mesothelial cells release tumor-promoting factors that accelerate the process of peritoneal metastasis. We identified cancer-associated mesothelial cells (CAMs) that had tumor-promoting potential. Here, we found that plasminogen activator inhibitor-1 (PAI-1) induced the formation of CAMs, after which CAMs increasingly secreted the oncogenic factors interleukin-8 (IL-8) and C-X-C motif chemokine ligand 5 (CXCL5), further promoting the metastasis of ovarian cancer cells in a feedback loop. After the formation of CAMs, PAI-1 activated the nuclear factor kappa B (NFκB) pathway in the CAMs, thus transcriptionally upregulating the expression of the downstream NFκB targets IL-8 and CXCL5. Moreover, PAI-1 correlated with peritoneal metastasis in ovarian cancer patients and indicated a poor prognosis. In both ex vivo and in vivo models, after PAI-1 expression was knocked down, the metastasis of ovarian cancer cells decreased significantly. Therefore, targeting PAI-1 may provide a potential target for future therapeutics to prevent the formation of CAMs and alleviate peritoneal metastasis in ovarian cancer patients. Highlights: Metastatic ovarian cancer cells actively interact with normal peritoneal mesothelial cells. Plasminogen activator inhibitor-1 is one of the secretory affecting factors. Cancer-associated mesothelial cellsAbstract: The mesothelium, covered by a continuous monolayer of mesothelial cells, is the first protective barrier against metastatic ovarian cancer. However, mesothelial cells release tumor-promoting factors that accelerate the process of peritoneal metastasis. We identified cancer-associated mesothelial cells (CAMs) that had tumor-promoting potential. Here, we found that plasminogen activator inhibitor-1 (PAI-1) induced the formation of CAMs, after which CAMs increasingly secreted the oncogenic factors interleukin-8 (IL-8) and C-X-C motif chemokine ligand 5 (CXCL5), further promoting the metastasis of ovarian cancer cells in a feedback loop. After the formation of CAMs, PAI-1 activated the nuclear factor kappa B (NFκB) pathway in the CAMs, thus transcriptionally upregulating the expression of the downstream NFκB targets IL-8 and CXCL5. Moreover, PAI-1 correlated with peritoneal metastasis in ovarian cancer patients and indicated a poor prognosis. In both ex vivo and in vivo models, after PAI-1 expression was knocked down, the metastasis of ovarian cancer cells decreased significantly. Therefore, targeting PAI-1 may provide a potential target for future therapeutics to prevent the formation of CAMs and alleviate peritoneal metastasis in ovarian cancer patients. Highlights: Metastatic ovarian cancer cells actively interact with normal peritoneal mesothelial cells. Plasminogen activator inhibitor-1 is one of the secretory affecting factors. Cancer-associated mesothelial cells are transformed from normal mesothelial cells during the interaction. As a response, cancer-associated mesothelial cells release oncogenic factors to accelerate the peritoneal metastasis. The activation of nuclear factor κB pathway in cancer-associated mesothelial cells accounts for the tumor-promoting effect. … (more)
- Is Part Of:
- Cancer letters. Volume 442(2019)
- Journal:
- Cancer letters
- Issue:
- Volume 442(2019)
- Issue Display:
- Volume 442, Issue 2019 (2019)
- Year:
- 2019
- Volume:
- 442
- Issue:
- 2019
- Issue Sort Value:
- 2019-0442-2019-0000
- Page Start:
- 181
- Page End:
- 192
- Publication Date:
- 2019-02-01
- Subjects:
- Ovarian cancer -- Cancer-associated mesothelial cells -- Plasminogen activator inhibitor-1 -- Peritoneal metastasis -- Microenvironment
CAMs cancer-associated mesothelial cells -- HPMCs human peritoneal mesothelial cells -- MMT mesothelial-mesenchymal transition -- CM conditioned medium -- FIGO stage the International Federation of Gynecologists & Obstetricians for staging a particular gynecologic cancer -- IL-8 interleukin-8 -- CXCL5 C-X-C motif chemokine ligand 5 -- NFκB transcription factor of nuclear factor kappa B -- TGF-β transforming growth factor beta -- RT-qPCR reverse transcription quantitative polymerase chain reaction
Cancer -- Periodicals
Neoplasms -- Periodicals
Cancer -- Périodiques
Electronic journals
616.994 - Journal URLs:
- http://www.sciencedirect.com/science/journal/03043835/ ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.canlet.2018.10.027 ↗
- Languages:
- English
- ISSNs:
- 0304-3835
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3046.485000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 9290.xml